Literature DB >> 26492443

Factor V Leiden.

Elizabeth M Van Cott1, Bernard Khor1, James L Zehnder2.   

Abstract

Factor V Leiden (FVLeiden ) is a common hereditary thrombophilia that causes activated protein C (APC) resistance. This review describes many of the most fascinating features of FVLeiden , including background features, mechanisms of hypercoagulability, the founder mutation concept, the "FVLeiden paradox," synergistic interaction with other thrombotic risk factors, the intertwined relationship between FVLeiden and APC resistance testing, and other, uncommon mutations implicated in causing APC resistance. In addition, there are several conditions where laboratory tests for APC resistance and FVLeiden are or can be discrepant, including lupus anticoagulants, anticoagulants such as direct thrombin inhibitors (dabigatran, argatroban, and bivalirudin) and rivaroxaban, as well as pseudohomozygous, pseudo-wildtype, liver transplant, and bone marrow transplant patients. The laboratory test error rate for FVLeiden is also presented.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26492443     DOI: 10.1002/ajh.24222

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  14 in total

1.  Effect of dabigatran on a prothrombinase-based assay for detecting activated protein C resistance: an ex vivo and in vitro study in normal subjects and factor V Leiden carriers.

Authors:  Gianluca Gessoni; Sara Valverde; Letizia Valle; Pierpaolo Caruso; Francesca Gessoni; Roberto Valle
Journal:  Blood Transfus       Date:  2017-03-07       Impact factor: 3.443

Review 2.  Thrombophilia testing in the era of direct oral anticoagulants.

Authors:  Jennifer Darlow; Holly Mould
Journal:  Clin Med (Lond)       Date:  2021-09-07       Impact factor: 5.410

3.  Genetic susceptibility to cerebrovascular disease: A systematic review.

Authors:  Christoph J Griessenauer; Sean Farrell; Atom Sarkar; Ramin Zand; Vida Abedi; Neil Holland; Andrew Michael; Christopher L Cummings; Raghu Metpally; David J Carey; Oded Goren; Neil Martin; Philipp Hendrix; Clemens M Schirmer
Journal:  J Cereb Blood Flow Metab       Date:  2018-09-05       Impact factor: 6.200

Review 4.  Targeting activated protein C to treat hemophilia.

Authors:  Stéphanie G I Polderdijk; Trevor P Baglin; James A Huntington
Journal:  Curr Opin Hematol       Date:  2017-09       Impact factor: 3.284

5.  A case of pulmonary thromboembolism due to coagulation factor V Leiden in Japan ~ usefulness of next generation sequencing~.

Authors:  Daisuke Sueta; Miwa Ito; Mitsuhiro Uchiba; Kenji Sakamoto; Eiichiro Yamamoto; Yasuhiro Izumiya; Sunao Kojima; Koichi Kaikita; Satoru Shinriki; Seiji Hokimoto; Hirotaka Matsui; Kenichi Tsujita
Journal:  Thromb J       Date:  2017-03-14

6.  Factor V G1691A is associated with an increased risk of retinal vein occlusion: a meta-analysis.

Authors:  Yuanyuan Zou; Xi Zhang; Jingyi Zhang; Xiangning Ji; Yuqing Liu
Journal:  Oncotarget       Date:  2017-09-04

Review 7.  A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis.

Authors:  Steven Bell; Andreas S Rigas; Magnus K Magnusson; Egil Ferkingstad; Elias Allara; Gyda Bjornsdottir; Anna Ramond; Erik Sørensen; Gisli H Halldorsson; Dirk S Paul; Kristoffer S Burgdorf; Hannes P Eggertsson; Joanna M M Howson; Lise W Thørner; Snaedis Kristmundsdottir; William J Astle; Christian Erikstrup; Jon K Sigurdsson; Dragana Vuckovic; Khoa M Dinh; Vinicius Tragante; Praveen Surendran; Ole B Pedersen; Brynjar Vidarsson; Tao Jiang; Helene M Paarup; Pall T Onundarson; Parsa Akbari; Kaspar R Nielsen; Sigrun H Lund; Kristinn Juliusson; Magnus I Magnusson; Michael L Frigge; Asmundur Oddsson; Isleifur Olafsson; Stephen Kaptoge; Henrik Hjalgrim; Gudmundur Runarsson; Angela M Wood; Ingileif Jonsdottir; Thomas F Hansen; Olof Sigurdardottir; Hreinn Stefansson; David Rye; James E Peters; David Westergaard; Hilma Holm; Nicole Soranzo; Karina Banasik; Gudmar Thorleifsson; Willem H Ouwehand; Unnur Thorsteinsdottir; David J Roberts; Patrick Sulem; Adam S Butterworth; Daniel F Gudbjartsson; John Danesh; Søren Brunak; Emanuele Di Angelantonio; Henrik Ullum; Kari Stefansson
Journal:  Commun Biol       Date:  2021-02-03

8.  Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19.

Authors:  Jun Wang; Prasanti Kotagiri; Paul A Lyons; Rafia S Al-Lamki; Federica Mescia; Laura Bergamaschi; Lorinda Turner; Michael D Morgan; Fernando J Calero-Nieto; Karsten Bach; Nicole Mende; Nicola K Wilson; Emily R Watts; Patrick H Maxwell; Patrick F Chinnery; Nathalie Kingston; Sofia Papadia; Kathleen E Stirrups; Neil Walker; Ravindra K Gupta; David K Menon; Kieren Allinson; Sarah J Aitken; Mark Toshner; Michael P Weekes; James A Nathan; Sarah R Walmsley; Willem H Ouwehand; Mary Kasanicki; Berthold Göttgens; John C Marioni; Kenneth G C Smith; Jordan S Pober; John R Bradley
Journal:  iScience       Date:  2022-02-22

Review 9.  Vaccine-induced immune thrombotic thrombocytopenia after vaccination against Covid-19: A clinical dilemma for clinicians and patients.

Authors:  Zeinab Mohseni Afshar; Arefeh Babazadeh; Alireza Janbakhsh; Mandana Afsharian; Kiarash Saleki; Mohammad Barary; Soheil Ebrahimpour
Journal:  Rev Med Virol       Date:  2021-07-01       Impact factor: 11.043

Review 10.  Coagulation, Microenvironment and Liver Fibrosis.

Authors:  Niccolò Bitto; Eleonora Liguori; Vincenzo La Mura
Journal:  Cells       Date:  2018-07-24       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.